KONEXChemicals066830

Genotech

₩1,200 0.00%2026-11-18 close
Market Cap
₩6.8B
Turnover
₩339,600
Volume
311 shares
Shares out.
5.7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Molecular Diagnostics Pivot Amid Persistent Losses

Revenue has stalled in the KRW 2.4–2.8 billion range with continued operating losses, leaving the expansion of genetic-variant precision diagnostics as the key variable for Genotech.

  1. 1

    Based on the 2025 disclosed results, revenue was KRW 2,563 million, up slightly from 2024 (KRW 2,454 million) but still about half the 2022 level (KRW 5,206 million).

  2. 2

    The company posted an operating loss of KRW 870 million and a net loss of KRW 1,146 million in 2025, with the net loss exceeding the operating loss, indicating additional non-operating losses.

  3. 3

    Total equity declined from KRW 11.45 billion in 2023 to KRW 9.55 billion in 2025, while the debt ratio stayed low at 10.01% in 2025.

  4. 4

    According to fnguide, the molecular diagnostics market is projected to grow at an annual rate of 11.4% through 2028, with the oncology segment projected at 26.9%.

  5. 5

    Largest shareholders and related parties hold 48.36%, and trading value is recorded at zero, indicating a limited float and thin liquidity.

02

Business structure

Genotech was founded in 1997, is headquartered in Daejeon and has been listed on KONEX since July 2016. The company's core business is synthetic DNA service, centered on supplying oligonucleotides as basic biomaterials.

It also offers large-scale sequencing analysis and is expanding into the development and production of genetic-variant precision diagnostic kits.

In pharmaceuticals, it holds manufacturing approvals for teicoplanin and silastatin sodium active ingredients, and has a licensing history for an anticancer biopharmaceutical material. Detailed revenue shares by segment are limited in public data.

In 2023, however, revenue from synthetic gene products fell 53.59% year on year, and gene analysis service revenue dropped 24.47%. By industry code the company sits in chemical manufacturing, but its operations are closer to genomics and diagnostics.

Genomics peers such as Synthego-type gene synthesis players are not the reference here; the named genomics comparables include Shintecabio and Macrogen, and competition in gene synthesis and analysis services is intensifying. Headcount stood at 31 as of August 2026.

03

Recent trends

Genotech approved its 29th-term financial statements at the annual general meeting held on March 23, 2026. Based on the 2025 standalone disclosure, revenue was KRW 2,563 million, operating loss was KRW 870 million and net loss was KRW 1,146 million.

Revenue in 2024 was KRW 2,454 million with a net loss of KRW 760 million. In 2023, revenue was KRW 2,750 million and the net loss was KRW 263 million. In 2022, revenue was KRW 5,206 million with net income of KRW 1,755 million, and revenue has since fallen to roughly half that level.

At the end of 2025, total assets were KRW 10,504 million, total liabilities were KRW 955 million and total equity was KRW 9,549 million. Equity had fallen from KRW 11,455 million in 2023 and KRW 10,695 million in 2024.

Operating cash flow in 2024 was negative KRW 415 million, and investing cash flow was negative KRW 448 million. The same meeting approved an articles amendment adding medical device development, manufacturing and sales to the business purpose, which the company cited as the reason for the change. The share price stood at 1,199 won, within a 52-week range of 805 to 1,600 won.

04

Outlook

The March 2026 approval of an articles amendment adding medical device businesses created the corporate basis to widen the company's scope into diagnostic equipment. The effect of this amendment has not yet appeared in disclosed revenue figures.

The molecular diagnostics market is projected to grow at an annual rate of 11.4% through 2028, with the oncology segment projected at 26.9%, according to fnguide. The company is pushing to expand its genetic-variant precision diagnostics business within that market.

However, with revenue stalled in the KRW 2.4–2.8 billion range, continued operating losses keep equity under pressure. The larger 2025 net loss compared with 2024 remains a burden on this structure. Two convertible bonds are recorded, which could become a variable for the capital structure. The next checkpoints are the 2026 third-quarter report and the 2026 fiscal year results disclosure.

05

Bull factors

Molecular diagnostics growth and oncology niche

According to fnguide, the molecular diagnostics market is projected to grow at an annual rate of 11.4% through 2028. The oncology segment is projected to grow faster at 26.9% a year, and Genotech is expanding its genetic-variant precision diagnostics business.

Because it combines synthetic gene supply with diagnostic kits, the company could capture a broader share of that growth.

Low leverage and a stable equity base

Based on 2025 data, the debt ratio was 10.01% and the reserve ratio was 236.98%, according to fnguide. Total liabilities of KRW 955 million are small relative to total equity of KRW 9,549 million. The low leverage suggests limited near-term borrowing pressure even with continued losses.

Pharmaceutical approvals and GMP track record

The company holds manufacturing approvals for the teicoplanin and silastatin sodium active ingredients and obtained GMP designation for pharmaceutical active ingredient synthesis in 2014. It also has a licensing history for an anticancer biopharmaceutical material.

These approvals support the company's credibility as a small biomaterials business. However, the disclosed figures do not separate how much these assets contribute to revenue.

06

Bear factors

Structural shrinkage in revenue

Revenue fell from KRW 5,206 million in 2022 to KRW 2,750 million in 2023 and KRW 2,454 million in 2024. It edged up to KRW 2,563 million in 2025 but remains well below the 2022 level. In 2023, revenue from synthetic gene products fell 53.59% year on year, and gene analysis service revenue dropped 24.47%. If the revenue base does not recover, the cost structure could remain a burden.

Persistent operating and net losses

The company recorded an operating loss of KRW 870 million and a net loss of KRW 1,146 million in 2025. The operating loss in 2024 was KRW 963 million. According to fnguide, intensifying competition and higher R&D costs are cited as the background to weak results. The net loss exceeding the operating loss indicates that non-operating losses were added.

Shrinking equity and negative cash flows

Total equity declined from KRW 11,455 million in 2023 to KRW 10,695 million in 2024 and KRW 9,549 million in 2025. Operating cash flow in 2024 was negative KRW 415 million. Investing cash flow was also negative at KRW 448 million. If cash generation does not recover, the decline in equity could continue.

07

Risk factors

Macro

Interest rate conditions and shifts in investor sentiment toward domestic biotech could affect price volatility in small KONEX-listed stocks. Although Genotech is classified under chemicals, its results and business trajectory are also shaped by the biotech diagnostics sector. A prolonged slowdown could constrain R&D spending and the pace of new business initiatives.

Trading value is recorded at zero, and largest shareholders and related parties hold 48.36% of shares. With a limited float, price moves may be exaggerated by gaps in the order book. The largest shareholder's stake was last changed on August 7, 2024.

The articles amendment adds medical device business, but licensing and commercialization require time and capital. Research and development costs may persist until the business transition produces results. Two convertible bonds are recorded, so future share dilution remains possible.

08

Overall view

Genotech is a small biotech company whose 2025 revenue remained in the KRW 2.5 billion range, with continued operating and net losses. The decline in synthetic gene and analysis service revenue was the starting point of weak results, and revenue has since stalled in the KRW 2.4–2.8 billion range.

On the bullish side, the molecular diagnostics growth outlook, low leverage and pharmaceutical approval history are cited. On the bearish side, continued losses, shrinking equity and negative operating cash flow stand out.

With medical device business added to the articles in March 2026, whether the new business can change the revenue structure is the central variable. However, the effect of this transition is not yet reflected in disclosed figures. This summary is provided for information only and consolidates disclosed figures and industry data.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. m.news.nate.com
  2. comp.fnguide.com
  3. lab.incruit.com
  4. incruit.com
  5. m.jobkorea.co.kr
  6. investing.com
  7. thevc.kr
  8. prestocknews.com
  9. catch.co.kr
  10. youtube.com
  11. markets.hankyung.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis